Acurx gets FDA conditional brand name acceptance for CDI drug

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. GOOGL
9. RTX
10. S

Go back to Acurx gets FDA conditional brand name acceptance for CDI drug

Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat

August 17, 2026 8:01 AM EDT

The proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTOThese initial milestones will form the basis for the commercial identity of Acurx's lead product candidate, ibezapolstat, as the Company prepares to advance it toward its international Phase 3 registration program for both the acute treatment and reduction of recurrence in C. difficile Infection (CDI)As required, a request for final FDA review and approval of the brand name will be submitted at time of marketing application for the... More